Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis.

Keith DunnRachel RogersRichard Bruce SimonsonDonghan LuoShubin ShengPurnima T KassamSareh SeyedkazemiHélène Hardy

Published in: HIV research & clinical practice (2021)

High rates of viral suppression during acute/early infection were achieved with D/C/F/TAF rapid initiation, no treatment-emergent resistant mutations were observed, and D/C/F/TAF was safe and well tolerated.

Keyphrases

liver failure
respiratory failure
drug induced
aortic dissection
antiretroviral therapy
sars cov
loop mediated isothermal amplification
hepatitis b virus
randomized controlled trial
study protocol
quantum dots
replacement therapy
smoking cessation